期刊文献+

急性冠脉综合征合并肾功能不全患者远期预后研究 被引量:2

Long-term outcomes in acute coronary syndrome patients with or without renal dysfunction
暂未订购
导出
摘要 目的:探讨急性冠脉综合征患者的肾功能对远期预后的影响。方法:选取2010年1月至2011年12月在东南大学附属中大医院心脏科住院治疗的390例急性冠脉综合征患者,分为急性ST段抬高心肌梗死( n=171)和不稳定心绞痛/非 ST 段抬高心肌梗死( n =219)两组,每组根据肾小球滤过率( estimated glomerular filtration rate , eGFR)分为eGFR正常组[ eGFR≥90 ml· min-1·(1.73 m)-2]和eGFR降低组[ eGFR<90 ml· min -1·(1.73 m)-2]两个亚组。分析各亚组病变血管情况、临床生化指标、合并症以及治疗情况,并对所有患者进行12~36个月随访,观察各组远期严重心血管不良事件的发生情况。结果:急性ST段抬高心肌梗死患者中,eGFR正常患者108例,34例(31.5%)出现严重心血管不良事件;eGFR降低者63例,26例(41.3%)出现严重心血管不良事件,两亚组严重心血管不良事件发生率差异无统计学意义(风险比1.426,95%置信区间0.855~2.378,P=0.174)。12~36个月随访中两亚组严重心血管不良事件发生风险差异无统计学意义(P=0.065),但eGFR降低组患者的严重心血管不良事件发生率呈现明显的上升趋势。不稳定心绞痛/非ST段抬高心肌梗死患者中,eGFR正常者140例,41例(38.0%)发生严重心血管不良事件;eGFR降低者79例,18例(28.6%)出现严重心血管不良事件,两亚组严重心血管不良事件发生率差异无统计学意义(风险比0.836,95%置信区间0.480~1.455,P=0.526)。12~36个月随访两亚组严重心血管不良事件发生风险差异无统计学意义( P=0.522)。结论:肾功能不全的急性心肌梗死患者远期发生严重心血管不良事件的风险与肾功能正常患者相比有上升趋势,但尚无统计学意义。 Objective:To determine the long-term outcomes in acute coronary syndrome ( ACS) patients with or without chronic kidney disease (CKD).Methods:390 ACS patients who were treated in Zhongda Hospital from Jan, 2010 to Dec, 2011 were enrolled in the study .These patients were divided into two groups: ST elevated myocardial infarction(STEMI) group ( n =171) and non ST elevated myocardial infarction ( non-STEMI) group ( n=219 ) .Each group was divided into two subgroups according to the estimated glomerular filtration rate (eGFR):normal eGFR subgroup[eGFR≥90 ml· min -1· (1.73 m) -2] and low eGFR subgroup[eGFR〈90 ml· min-1· (1.73 m) -2].Basic clinical characters were analyzed and major adverse cardiovascular events (MACEs) were observed during 12 -36 months follow-up.Results: In STEMI group, 108 patients had normal renal function , MACEs happened in 34 patients ( 31 .5%) .63 patients had renal dysfunction , MACEs happened in 26 patients(41.3%) .The incidence of MACEs had no significant difference between two subgroups ( Hazard ratio 1.426, 95% confidence interval 0.855 -2.378, P=0.174).The cumulative hazard of MACEs between two subgroups had no significant difference ( P=0 .065 ) .However , increasing trend of MACEs incidence was observed in low eGFR subgroup .In non-STEMI group , 140 patients had normal renal function , MACEs happened in 41 patients(38.0%).79 patients had renal dysfunction , MACEs happened in 18 patients(28.6%).The incidence of MACEs had no significant difference between two subgroups ( Hazard ratio 0.836, 95% cofidence interval 0.480-1.455, P =0.526 ).The cumulative hazard of MACEs between two subgroups had no significant difference(P=0.522).Conclusion:STEMI patients with renal dysfunction have increased risk of MACEs in long term follow-up compared with normal renal function , although statistical significant was not detected .
出处 《东南大学学报(医学版)》 CAS 2014年第3期267-271,共5页 Journal of Southeast University(Medical Science Edition)
基金 国家自然科学基金资助项目(81270204)
关键词 急性冠脉综合征 肾小球滤过率 严重心血管不良事件 acute coronary syndrome estimated glomerular filtration rate major adverse cardiovascular events
  • 相关文献

参考文献23

  • 1HE J,GU D, WU X, et al. Major causes of death among men and women in China [ J ]. N Engl J Med, 2005,353 ( 11 ) :1124-1134.
  • 2ZHANG L, WANG F, WANG L, et al. Prevalence of chronic kidney disease in China:a cross-sectional survey[ J ]. Lancet, 2012,379(9818) :815-822.
  • 3GRAND'MAISON A, CHAREST A F, GEERTS W H. An- ticOagulant use in patients with chronic renal impairment[ J ]. Am J Cardiovasc Drugs,2005(5) :291-305.
  • 4EZEKOWITZ J, MCALISTER F A, HUMPHRIES K H, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failureand coronary artery disease [ J ]. J Am Coil Cardiol, 2004,44 ( 8 ) : 1587 - 1592.
  • 5MEHRAN R, NIKOLSKY E, LANSKY A J, et al. Impact of chronic kidney disease on early ( 30" day ) and late ( 1 - year ) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies:an ACUI- TY ( Acute Catheterization and Urgent Intervention Triage strat- egy) substudy [ J ]. JACC Cardiovasc Interv, 2009,2 ( 8 ) : 748-757.
  • 6SAGRIPANTI A, COZZA V, BAICCHI U, et al. Increased thrombin generation in patients with chronic renal failure [ J ]. Int J Clin Lab Res, 1997,27 ( 1 ) :72-75.
  • 7POULIKAKOS D, BANERJEE D, MALIK M. Risk of sudden cardiac death in chronic kidney disease [ J ]. J Cardiovasc Electrophysiol,2013 [ Epub ahead of print ].
  • 8KOUSHOLT B S. Natriuretic peptides as therapy in cardiac is- chaemia/repeffusion [ J ]. Dan Med J,2012,59 (6) : B4469.
  • 9STEG P G,JAMES S K,ATAR D,et al. Third universal defini- tion of myocardial infarction[ J ]. Cur Heart J, 2012,80 (12) : 777-786.
  • 10HOCHHOLZER W, WIVIOTT S D, ANTMAN E M, et al. Predictors of bleeding and time dependence of association of bleeding with mortality:insights from the Trial to Assess Im- provement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarc- tion 38 ( TRITON- TIMI 38 ) [ J ]. Circulation, 2011, 123 ( 23 ) :2681-2689.

二级参考文献13

  • 1EIGLER N, PFAFF J M, WHITING J, et al. The role of digital angiography in the evaluation of coronary artery disease [ J ]. Int J Cardiol,1986,10 ( 1 ) :3-13.
  • 2ARONOW H D, QUINN M J, GURM H S, et al. Preprocedure inflammatory state predicts periprocedural myocardial infarction after elective percutaneous coronary intervention: an EPIC substudy[J]. Am J Cardiol,2003,41 (Suppl A) :17A.
  • 3DANESH J, WHEELER J G, HIRSCHFIELD G M, et al. C- reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease [ J ]. N Engl J Med, 2004,350 (14) : 1387- 1397.
  • 4PASCERI V,WILLERSON J T,YEH E T. Direct proinflammatory effect of C-reactive protein on human endothelial cells [ J ]. Circulation,2000,102 (18) :2165-2168.
  • 5SOLYMOSS B C, BOURASSA M G, CAMPEAU L A, et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity [J]. Am J Cardiol,2004,93 (2) :159-164.
  • 6GLASSER S P,SELWYN A P,GANZ P,et al.Atherosclerosis:risk factors and the vascular endothelium[J].Am Heart J,1996,131:379-382.
  • 7DETRY J M,SELLIER P,PENNAFORTE S,et al.Trimetazidine:a new concept in the treatment of angina.Comparison with propranolol in patients with stable angina.Trimetazidine European Multicenter Study Group[J].Br J Clin Pharmaco1,1994,37(3):279-288.
  • 8De LEIRISJ,BOUCHER F.Rationale for trimetazidine administration in myocardial ischemia-reperfusion syndrome[J].Eur Heart J,1993,14(Suppl G):34-40.
  • 9BANANI H,BERNARD M,BAETZ D,et al.Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidime.Comparison between 1ow-and zero-flow ischaemia[J].Cardiovasc Res,2000,47(4):688-696.
  • 10ARROYO-ESPLIGUERO R,AVANZAS P,COSIN-SALES J,et al.C-reactive protein elevation and disease activity in patients with coronary artery disease[J].Eur Heart J,2004,25:401-408.

共引文献33

同被引文献9

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部